Enfermedad pulmonar intersticial asociada a esclerosis sistémica (EPI-ES)
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of skin fibrosis: further analyses of the SENSCIS trial
Allanore et al.
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and normal versus elevated C-reactive protein (CRP) at baseline: analyses from the SENSCIS trial
Reimekasten et al.
Is there a difference between the sexes in the rate of progression of systemic sclerosis-associated ILD (SSc-ILD)? Data from the SENSCIS trial
Volkmann et al.
Is the rate of lung function decline the same in patients with systemic sclerosis-associated ILD (SSc-ILD) who experience weight loss? Data from the SENSCIS trial
Lescoat et al.
Correlation between progression of skin fibrosis and progression of interstitial lung disease (ILD) in patients with SSc-ILD: data from the SENSCIS trial
Distler et al.
Community advisory board input can make lay summaries of clinical trial results more understandable
Welling et al.
